Theratechnologies annonce des données préliminaires de tolérabilité et d’efficacité provenant de l’essai de détermination de la dose de phase Ib portant sur le sudocétaxel zendusortide mené chez des patientes atteintes d’un cancer de l’ovaire avancé
December 09, 2024 07:30 ET
|
Theratechnologies
Aucune toxicité limitant la dose n’a été signalée en lien avec deux doses hebdomadaires différentes chez des patientes fortement prétraitées Données probantes préliminaires concernant la relation...
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
December 09, 2024 07:30 ET
|
Theratechnologies
No dose-limiting toxicities reported in two different weekly doses in heavily pre-treated patients Preliminary evidence of dose response includes significant tumor shrinkage and one patient with...
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
October 03, 2024 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
September 14, 2024 03:00 ET
|
Immunocore Holdings plc
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
September 14, 2024 03:00 ET
|
Sutro Biopharma, Inc.
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...
UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
September 09, 2024 16:06 ET
|
Imunon, Inc.
September 18th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline ...
AI in Oncology Market Size is Projected to Reach USD 7.7 billion by 2034, Growth at CAGR 16.8% | Report by Transparency Market Research, Inc.
September 02, 2024 05:40 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 02, 2024 (GLOBE NEWSWIRE) -- The global AI in oncology market (종양학 시장의 AI) is estimated to thrive at a CAGR of 16.8%...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 16, 2024 07:00 ET
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August...
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
July 30, 2024 07:00 ET
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor
June 25, 2024 08:07 ET
|
Cybrexa Therapeutics
NEW HAVEN, Conn., June 25, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...